Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results

被引：0

作者：

Benn, P. ^{[1
]}

Quercia, R. ^{[2
]}

Hudson, K. ^{[3
]}

Wang, Y. ^{[4
]}

Chounta, V. ^{[5
]}

Talarico, C. ^{[6
]}

Ford, S. ^{[7
]}

Cutrell, A. ^{[8
]}

Margolis, D. ^{[9
]}

Van Solingen-Ristea, R. ^{[10
]}

Vanveggel, S. ^{[10
]}

Van Eygen, V. ^{[10
]}

Polli, J. ^{[11
]}

de Ruiter, A. ^{[11
]}

Smith, K. ^{[12
]}

Spreen, W. ^{[9
]}

机构：

[1] ViiV Healthcare, Clin Dev, Brentford, England

[2] ViiV Healthcare, Clin Virol, Brentford, England

[3] ViiV Healthcare, Clin Dev, Res Triangle Pk, NC USA

[4] GlaxoSmithKline, Stat, R&D, Collegeville, PA USA

[5] ViiV Healthcare, Global Hlth Outcomes, Brentford, England

[6] ViiV Healthcare, Translat Med Res, Res Triangle Pk, NC USA

[7] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Res Triangle Pk, NC USA

[8] ViiV Healthcare, Stat, R&D, Res Triangle Pk, NC USA

[9] ViiV Healthcare, Clin Dev, R&D, Res Triangle Pk, NC USA

[10] Janssen Res & Dev, Clin R&D, Beerse, Belgium

[11] ViiV Healthcare, Global Med Sci, Res Triangle Pk, NC USA

[12] ViiV Healthcare, R&D, Res Triangle Pk, NC USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P017

引用

页码：28 / 29

页数：2

共 50 条

[31] Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
Swindells, Susan
Lutz, Thomas
Van Zyl, Lelanie
Porteiro, Norma
Stoll, Matthias
Mitha, Essack
Shon, Alyssa
Benn, Paul
Huang, Jenny O.
Harrington, Conn M.
Hove, Kai
Ford, Susan L.
Talarico, Christine L.
Chounta, Vasiliki
Crauwels, Herta
Van Solingen-Ristea, Rodica
Vanveggel, Simon
Margolis, David A.
Smith, Kimberly Y.
Vandermeulen, Kati
Spreen, William R.
AIDS, 2022, 36 (02) : 185 - 194
[32] CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING ANTIRETROVIRAL THERAPY ADMINISTERED EVERY 2-MONTHS IS COST EFFECTIVE FOR THE TREATMENT OF HIV-1 IN SPAIN
Moreno Guillen, S.
Rivero, A.
Ventayol, P.
Falco, V.
Torralba, M.
Schroeder, M.
Neches, V.
Vallejo-Aparicio, L. A.
Mackenzie, I.
Turner, M.
Harrison, C.
VALUE IN HEALTH, 2022, 25 (12) : S122 - S122
[33] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
Moreno, Santiago
Rivero, Antonio
Ventayol, Pere
Falco, Vicenc
Torralba, Miguel
Schroeder, Melanie
Neches, Victoria
Vallejo-Aparicio, Laura Amanda
Mackenzie, Isaac
Turner, Matthew
Harrison, Cale
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (08) : 2039 - 2055
[34] The implementation of every-2-months cabotegravir and rilpivirine long-acting injections from the perspective of healthcare providers in the German CARLOS cohort, 6-month outcomes
Scherzer, J.
Jonsson-Oldenbuettel, C.
Schneeweiss, S.
Wyen, C.
Borch, J.
Ummard-Berger, K.
Postel, N.
Rodriguez, E.
Gutner, C.
Dymek, K.
Westermayer, B.
Bernhardt, K.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 40 - 41
[35] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
Santiago Moreno
Antonio Rivero
Pere Ventayol
Vicenç Falcó
Miguel Torralba
Melanie Schroeder
Victoria Neches
Laura Amanda Vallejo-Aparicio
Isaac Mackenzie
Matthew Turner
Cale Harrison
Infectious Diseases and Therapy, 2023, 12 : 2039 - 2055
[36] Long-acting cabotegravir (CAB) plus rilpivirine (RPV) in the first, virologically-suppressed adolescents with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational Study: IMPAACT 2017 week 48 outcomes
Gaur, A.
Baltrusaitis, K.
Capparelli, E.
Moye, J.
Yin, D.
Violari, A.
Heckman, B.
Buisson, S.
Van Solingen-Ristea, R.
Harrington, C.
Marzinke, M.
Lowenthal, E.
Ward, S.
Milligan, R.
Best, B.
Townley, E.
Agwu, A.
McCoig, C.
Roberts, G.
Huang, J.
Cheung, A.
Crauwels, H.
Van Eygen, V.
Krotje, C.
Zabih, S.
Masheto, G.
Ounchanum, P.
Aurpibul, L.
Korutaro, V.
Moore, C. Bolton
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 88 - 89
[37] Perspectives on the acceptability, appropriateness, feasibility, barriers, and facilitators from patients receiving cabotegravir plus rilpivirine long-acting injectable treatment (CAB plus RPV LA): interim results from the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)
Hocqueloux, L.
Gutner, C.
DeMoor, R.
Gill, M.
Trehan, R.
D'Amico, R.
Tomkins, S.
Schroeder, M.
Bontempo, G.
Ait-Khaled, M.
Hadi, M.
Anand, S. Bakhshi
Low, E. L.
Jeanmaire, E.
Crusells Canales, M.
Vandekerckhove, L.
Bonnet, F.
Olalla Sierra, J.
Czarnogorski, M.
HIV MEDICINE, 2021, 22 : 99 - 99
[38] Indirect comparison of 96-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 2 months versus dolutegravir/abaca-vir/lamivudine in suppressed HIV-1 infected participants
Snedecor, S. J.
Schroeder, M. D.
Scherzer, J.
Van de Velde, N.
HIV MEDICINE, 2021, 22 : 119 - 119
[39] Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR)
Chounta, V.
Wu, S.
Upadhyay, O.
Griffith, S.
Harrington, C.
Orkin, C.
Swindells, S.
Spreen, W.
Margolis, D.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 24 - 24
[40] POTENTIAL HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS OF EVERY 2-MONTHS INJECTABLE CABOTEGRAVIR plus RILPIVIRINE LONG-ACTING IMPLEMENTATION IN THE SPANISH NHS VS DAILY ORAL HIV TREATMENTS
Vallejo-Aparicio, L. A.
Neches, V
Hernandez Novoa, B.
Casado, G.
Jodar, F.
Pinel, M.
Callejo-Velasco, D.
VALUE IN HEALTH, 2022, 25 (12) : S129 - S130

← 1 2 3 4 5 →